Condition: Pulmonary Embolism · Venous Thromboembolism · Sponsor: University Hospital, Brest
Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk. Little is known about this last group. Anticoagulation is efficient to prevent recurrence but is currently not recommended for patient with an intermediate risk of recurrence. Identifying risk factors of recurrent PE remains a major issue to identify sub-groups of patients who would require lifelong anticoagulation. In 30-40% of cases, PE patients develop residual pulmonary vascular obstruction (RPVO), which has been found to be associated with an increased recurrence risk. This last observation was mostly reported in patients with unprovoked PE (patients with high risk of recurrence) and RPVO was measured using conventional planar lung scan. In patients with an intermediate risk of recurrence, the impact of RPVO has been much less studied. In addition, the definition of RPVO was variable according to studies and correlation between RPVO burden and recurrence risk has not been clearly demonstrated. This might be explained by the inherent limitation of RPVO quantification using conventional planar imaging, which is only based on a visual estimation on 2-dimensional images. Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT) is a new method of scintigraphic image acquisition that offers the advantage of 3-dimensional imaging, enabling …
This description comes directly from the study's public registry record.
Pierre-Yves LE ROUX, Pr · +33298223327 · pierre-yves.leroux@chu-brest.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens | Amiens, France, France | Recruiting |
| CHU Angers | Angers, France, France | Active Not Recruiting |
| CHU Brest | Brest, France, France | Recruiting |
| Hôpital Louis MourierAP-HP | Colombes, France, France | Recruiting |
| CHD Vendée - La Roche sur Yon | La Roche-sur-Yon, France, France | Recruiting |
| Kremlin-Bicêtre AP-HP | Le Kremlin-Bicêtre, France, France | Active Not Recruiting |
| CH Les Sables d'Olonne | Les Sables-d'Olonne, France, France | Recruiting |
| Hegp Ap-Hp | Paris, France, France | Recruiting |
| CH Quimper | Quimper, France, France | Recruiting |
| CHU St-Etienne | Saint-Etienne, France, France | Recruiting |
| CHIC Toulon | Toulon, France, France | Recruiting |
| HIA Toulon | Toulon, France, France | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06372730